177 related articles for article (PubMed ID: 9075767)
21. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
[TBL] [Abstract][Full Text] [Related]
22. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol.
Cherpelis BS; Moore R; Ladd S; Chen R; Glass LF
Dermatol Surg; 2009 Feb; 35(2):207-13. PubMed ID: 19215257
[TBL] [Abstract][Full Text] [Related]
23. Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens.
Kupsch JM; Tidman N; Bishop JA; McKay I; Leigh I; Crowe JS
Melanoma Res; 1995 Dec; 5(6):403-11. PubMed ID: 8589614
[TBL] [Abstract][Full Text] [Related]
24. [Mouse monoclonal antibody (FKH1) detecting human melanoma-associated antigens: production, partial characterization and immunohistochemical analysis].
Fukaya T
Hokkaido Igaku Zasshi; 1991 May; 66(3):300-10. PubMed ID: 1885156
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A.
Giudice C; Ceciliani F; Rondena M; Stefanello D; Grieco V
J Vet Diagn Invest; 2010 May; 22(3):389-94. PubMed ID: 20453212
[TBL] [Abstract][Full Text] [Related]
26. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
27. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells.
Liao SK; Smith JW; Kwong PC; Natali PG; Kusama M; Hamby CV; Ferrone S
Cancer Res; 1987 Sep; 47(18):4835-41. PubMed ID: 3476198
[TBL] [Abstract][Full Text] [Related]
28. Workshop on monoclonal antibodies to human melanoma-associated antigens: findings of the Seattle group.
Hellström I; Brown JP; Hellström KE
Hybridoma; 1982; 1(4):399-402. PubMed ID: 6208136
[TBL] [Abstract][Full Text] [Related]
29. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.
Zubovits J; Buzney E; Yu L; Duncan LM
Hum Pathol; 2004 Feb; 35(2):217-23. PubMed ID: 14991540
[TBL] [Abstract][Full Text] [Related]
30. Development and characterization of a mouse monoclonal antibody, MoAb HMSA-1, against a melanosomal fraction of human malignant melanoma.
Akutsu Y; Jimbow K
Cancer Res; 1986 Jun; 46(6):2904-11. PubMed ID: 3516387
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical labeling of normal melanocytes.
Dean NR; Brennan J; Haynes J; Goddard C; Cooter RD
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):199-204. PubMed ID: 12373143
[TBL] [Abstract][Full Text] [Related]
32. Melanosomal antigenic expression on the cell surface and intracellular subunits within melanogenic compartments of pigment cells: analysis by antimelanosome-associated monoclonal antibody.
Hayashibe K; Mishima Y; Ichihashi M; Kawai M
J Invest Dermatol; 1986 Jul; 87(1):89-94. PubMed ID: 3522755
[TBL] [Abstract][Full Text] [Related]
33. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
34. Comparison of antibodies to MART-1 and MelanA in fine-needle aspiration samples of metastatic malignant melanoma.
Fetsch PA; Filie AC; Steinberg SM; Abati A
Diagn Cytopathol; 2001 Jul; 25(1):78-9. PubMed ID: 11466819
[No Abstract] [Full Text] [Related]
35. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1.
Kelley LC; Starkus L
J Am Acad Dermatol; 2002 Jan; 46(1):78-84. PubMed ID: 11756950
[TBL] [Abstract][Full Text] [Related]
36. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
Maeda K; Jimbow K
Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a novel neuroglandular antigen (NGA) expressed on abnormal human melanocytes.
Sikora LK; Pinto A; Demetrick DJ; Dixon WT; Urbanski SJ; Temple W; Jerry LM
Int J Cancer; 1987 Feb; 39(2):138-45. PubMed ID: 3804488
[TBL] [Abstract][Full Text] [Related]
38. Melan-A, a new melanocytic differentiation marker.
Busam KJ; Jungbluth AA
Adv Anat Pathol; 1999 Jan; 6(1):12-8. PubMed ID: 10197235
[TBL] [Abstract][Full Text] [Related]
39. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
Wong RM; Scotland RR; Lau RL; Wang C; Korman AJ; Kast WM; Weber JS
Int Immunol; 2007 Oct; 19(10):1223-34. PubMed ID: 17898045
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
